Palvella Therapeutics (PVLA) announced the successful completion of TOIVA, a Phase 2 trial of QTORIN 3.9% rapamycin anhydrous gel for the treatment of cutaneous venous malformations. The Phase 2 trial enrolled 16 subjects at leading vascular anomaly centers, meeting the original recruitment target of approximately 15 subjects. Top-line results from TOIVA are expected in mid-December 2025.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics initiated with an Outperform at Oppenheimer
- Palvella Therapeutics Accelerates U.S. Launch Planning
- Palvella Therapeutics appoints Osborne as Chief Innovation Officer
- Palvella Therapeutics price target raised to $66 from $52 at Canaccord
- Palvella Therapeutics price target raised to $75 from $38 at H.C. Wainwright